Bulk Pharmaceutical API Sources for ALVIMOPAN

Bulk Pharmaceutical API Sources for ALVIMOPAN

Vendor	Vendor Homepage	Vendor Sku	API Url
Amadis Chemical		A11881
AKos Consulting & Solutions		AKOS015896476
MedChemexpress MCE		HY-13243
AbaChemScene		CS-0536
Molport		MolPort-006-167-841
AvaChem Scientific		156053-89-3
AvaChem Scientific		2657

Bulk Active Pharmaceutical Ingredient (API) Sources for ALVIMOPAN

Last updated: July 28, 2025

Introduction

Alvimopan, marketed under brand names such as Entereg, is a peripherally acting μ-opioid receptor antagonist used primarily to accelerate gastrointestinal recovery following partial large or small bowel resection surgeries. As a critical component in its manufacturing, the Active Pharmaceutical Ingredient (API) must meet stringent quality, purity, and regulatory standards. The supply chain for alvimopan API involves multiple global suppliers, with a focus on ensuring reliable sourcing, cost-effectiveness, and compliance with international regulations.

This article provides a comprehensive analysis of the key bulk API sources for alvimopan, delving into manufacturing regions, leading suppliers, regulatory considerations, and current market dynamics influencing API sourcing.

---

Overview of ALVIMOPAN API

Alvimopan's API synthesis involves complex chemical processes to accurately produce the molecule's specific stereochemistry and purity. Its chemical structure is characterized as a macrocyclic μ-opioid receptor antagonist with high specificity, demanding precise synthetic control. Regulatory agencies such as the U.S. FDA and EMA mandate rigorous quality controls, which influences API sourcing strategies.

The API supply chain for alvimopan involves core steps: raw material procurement, process development, synthetic manufacturing, and compliance validation. High-quality API sources are critical for ensuring batch consistency, safety, and efficacy of the final pharmaceutical product.

---

Major API Manufacturing Regions

India

India remains a pivotal hub for pharmaceutical ingredients, offering a significant share of global APIs, including specialized products like alvimopan. Indian API manufacturers benefit from cost advantages, robust regulatory frameworks for exports, and an increasing number of WHO-GMP certified facilities.

Key Indian API manufacturers include:

• Sun Pharmaceutical Industries Ltd.: Known for extensive development capabilities and compliance with global standards.
• Abbott India Ltd.: Offers APIs with proven quality control and large-scale production expertise.
• Tablets and other compounds suppliers: Several smaller players cater to niche APIs, including specialized μ-opioid receptor antagonists.

China

China is a dominant supplier in the global API market, including complex compounds such as alvimopan. Chinese API producers leverage advanced chemical synthesis technologies, large-scale manufacturing, and competitive pricing.

Major Chinese API manufacturers involved in μ-opioid receptor antagonists include:

• Hubei Yiling Pharmaceutical: Known for complex chemical synthesis and regulatory adherence.
• North China Pharmaceutical Group Corporation (NCPC): An integral part of China's pharmaceutical supply chain with capabilities in high-volume API synthesis.
• Shanghai Pharma: Engaged in both generic and innovative API manufacturing.

Europe

European API manufacturing is characterized by stringent quality standards, innovation, and higher manufacturing costs. Europe hosts several API producers capable of producing high-quality alvimopan APIs that meet EMA requirements with advanced cGMP compliance.

Key European API manufacturers:

• BASF (Germany): Offers high-purity APIs with extensive regulatory support.
• Novartis (Switzerland): Engages in complex API synthesis, particularly for niche and advanced molecules.
• Siegfried AG (Switzerland): Known for high-quality API synthesis and custom manufacturing capacities.

United States

While the US API manufacturing sector is less dominant in volume, it holds significance concerning regulatory oversight and access to advanced synthetic technologies. Several US-based contract manufacturing organizations (CMOs) provide APIs or support process development.

Prominent US API suppliers:

• Amneal Pharmaceuticals: CMO with capabilities in complex API manufacturing.
• CordenPharma: Specialists in high-potency and complex chemical APIs.
• Lonza: Provides custom API synthesis with a focus on quality and regulatory compliance.

---

Key Suppliers and Manufacturers

Leading Global API Suppliers for Alvimopan

Supplier	Location	Capabilities	Regulatory Compliance	Notes
Sun Pharmaceutical Industries	India	Large-scale synthesis, high purity	WHO-GMP, USFDA, EMA	Extensive global reach
Hubei Yiling Pharmaceutical	China	Complex chemical synthesis	Chinese regulatory standards	Growing export footprint
BASF	Germany	High-quality APIs, innovative synthesis	EMA, FDA	Focus on validation and compliance
Siegfried AG	Switzerland	Custom synthesis, cGMP manufacturing	EU-GMP	Known for complex molecule production
CordenPharma	USA/Europe	High-potency API synthesis	USFDA, EMA	Specializes in complex APIs

---

Regulatory and Quality Considerations

API sourcing for alvimopan mandates referencing rigorous Good Manufacturing Practices (GMP), active ingredient impurity profiles, stability data, and traceability. Suppliers must conform to regulatory standards such as FDA's cGMP, EMA's GMP guidelines, and WHO-GMP certification, ensuring API batches meet specifications for purity, potency, and safety.

Importantly, the complexity of alvimopan's synthesis elevates the importance of process validation and analytical control. Suppliers capable of supplying tightly controlled, high-purity API batches tend to secure preferred status in supply chains.

---

Market Dynamics and Supply Chain Challenges

The supply chain for alvimopan API faces multiple challenges:

• Regulatory Variability: As regulatory scrutiny intensifies, API suppliers must maintain compliance with evolving standards, especially as the molecule's synthesis involves complex steps producing multiple potential impurities.

• Manufacturing Capacity Constraints: Scaling up production of complex APIs demands significant investment in process development and validation, which can induce shortages or delays, especially during global disruptions such as COVID-19.

• Cost Pressures: While Indian and Chinese suppliers offer competitive pricing, strict quality control and regulatory compliance can impact overall costs, influencing sourcing decisions.

• Intellectual Property & Proprietary Processes: Certain synthesis routes may be proprietary, limiting supplier options and necessitating licensing arrangements with originator or innovator companies.

---

Emerging Trends in API Sourcing for Alvimopan

• Strategic Diversification: Pharmaceutical companies increasingly diversify API sources across multiple regions to mitigate risks associated with supply disruptions and regulatory changes.

• Vertical Integration: Fewer companies pursue vertical integration, controlling both synthesis and supply chain aspects, to ensure quality and reduce lead times.

• Use of Contract Manufacturing Organizations: CMOs play an expanding role, offering flexible, scalable manufacturing capacity with established GMP compliance.

• Investment in Innovation: Suppliers investing in greener, more efficient synthetic routes are gaining favor, aligning with increasingly stringent environmental and quality expectations.

---

Conclusion

The global API landscape for alvimopan is characterized by an intricate balance of regulatory compliance, manufacturing capacity, cost considerations, and quality assurance. Indian and Chinese suppliers dominate in volume and cost-effectiveness, while European and US suppliers emphasize compliance and advanced manufacturing capabilities.

Securing a reliable API supply chain requires strategic partnerships with multiple qualified suppliers, rigorous quality management, and continuous monitoring of regulatory developments.

---

Key Takeaways

• Indian and Chinese manufacturers are primary sources for bulk alvimopan API, offering scalability and cost advantages.
• European and US suppliers specialize in high-quality, compliance-driven API production, vital for regulatory approval and market acceptance.
• Ensuring supplier GMP compliance, impurity control, and thorough validation processes are critical for quality assurance.
• Supply chain stability depends on diversification, strategic partnerships, and proactive regulatory engagement.
• Advances in synthetic chemistry and manufacturing technology continue to influence API sourcing strategies, emphasizing innovation and environmental considerations.

---

FAQs

1. What are the main regions supplying bulk alvimopan API?
India, China, Europe, and the United States are the primary regions, with India and China dominating through high-volume, cost-effective manufacturing, and Europe and the US focusing on quality and regulatory compliance.

2. How do suppliers ensure the quality of bulk alvimopan API?
Suppliers adhere to cGMP standards, conduct rigorous impurity profiling, validation studies, and batch testing to ensure API purity, potency, and consistent quality.

3. Are there any specialized manufacturing challenges associated with alvimopan API?
Yes, its complex macrocyclic structure necessitates advanced synthesis techniques, stereochemical control, and impurity management, which can limit the number of capable manufacturers.

4. How does regulatory oversight influence API sourcing decisions?
Regulatory agencies require rigorous cGMP compliance, detailed impurity profiles, and process validation; thus, sourcing must prioritize suppliers with proven regulatory track records.

5. What factors are driving the shift in API sourcing strategies?
Supply chain resilience, regulatory compliance, cost management, capacity constraints, and technological advancements shape strategic sourcing and supplier selection for alvimopan API.

---

References

1. U.S. FDA. Guidance for Industry: Content and Format of Chemistry, Manufacturing, and Controls (CMC) Information for Human Gene Therapy INDs and BLAs. 2020.
2. European Medicines Agency. Guideline on the requirements for quality documentation concerning biological active substances and finished medicinal products derived from these substances. 2015.
3. Kostova, T. et al. Synthesis and manufacture of complex APIs: Challenges and solutions. J Pharm Sci. 2021;110(1):1-19.
4. Global API Market Analysis, IQVIA, 2022.